6918 — A Plus Biotechnology Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareAdventurousSmall CapNeutral

Annual income statement for A Plus Biotechnology Co, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	PROSPECTUS	PROSPECTUS	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	503	542	615	675	770
Cost of Revenue
Gross Profit	318	346	374	461	535
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Total Operating Expenses	461	495	549	508	587
Operating Profit	42.5	46.7	67	168	182
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	47.7	46.1	68.1	45.5	188
Provision for Income Taxes
Net Income After Taxes	39	35.6	45.7	31.2	151
Minority Interest
Net Income Before Extraordinary Items
Net Income	36.1	32.9	45.7	31.2	151
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	36.1	32.9	45.7	31.2	151
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	1.18	1.08	1.5	1.03	4.97
Dividends per Share